View source for Carboplatin

{{TreatmentInfo
|drug_name=Carboplatin
|FDA_approval=Yes, approved for various cancers including ovarian and lung cancer; used off-label for GBM
|used_for=Recurrent Glioblastoma Multiforme (GBM) and high-grade glioma
|clinical_trial_phase=Exploratory and Phase 1/2 trials for recurrent glioma in combination with other agents
|common_side_effects=Less toxicity compared to cisplatin, but may include myelosuppression, nausea, and potential for liver enzyme elevation
|OS_without=Not specified
|OS_with=Not directly specified; ongoing studies aim to clarify Carboplatin's impact on survival in recurrent glioma
|PFS_without=Not applicable
|PFS_with=Early studies indicate variable results; ongoing trials, including combinations with PARP inhibitors, aim to determine efficacy
|usefulness_rating=Pending further clinical trials and data
|usefulness_explanation=Carboplatin, especially in combination with agents like Talazoparib, represents a promising line of investigation for recurrent GBM and high-grade glioma. Early research suggests variable efficacy, with the potential for meaningful clinical benefit in specific patient populations.
|toxicity_level=2
|toxicity_explanation=Carboplatin is generally preferred over cisplatin due to its significantly lower toxicity profile, though myelosuppression remains a concern. The combination with Talazoparib is under study to determine the safety and tolerability of this novel therapeutic approach.
|book_text=Carboplatin's role in treating recurrent glioma, including GBM, is under active exploration, with early studies and ongoing trials investigating its efficacy and safety in combination with other therapeutic agents. Its lower toxicity profile compared to other platinum-based chemotherapies, like cisplatin, makes it an attractive option for recurrent glioma treatment strategies, pending further evidence from current research efforts.
|category=Other chemotherapy agents at recurrence
}}